Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced that its Board of Directors (the “Board”) has ...

Integer Holdings (ITGR) launches a strategic review, weighing a sale/merger or standalone path; plus Q1 FY26 results beat on ...

First quarter results in line with February outlook ~~ Updates 2026 outlook ranges; continues to expect 200bps above-market organic sales ...

Medical technology company Integer Holdings (NYSE:ITGR) will be reporting results this Thursday morning. Here’s what to ...

Integer Holdings has begun a strategic review to consider a sale, merger, business combination, or continuing its standalone plan, following activist investor engagement and stronger-than-expected Q1 ...

Integer (NYSE:ITGR) reported first-quarter 2026 results that management said were in line with the outlook it provided in ...

Shares of Integer (NYSE: ITGR), a company specializing in the development and manufacturing of medical devices, saw a substantial decline of 32% on October 23, 2025. This notable drop was mainly due ...

Q1 2026 earnings call recap: updated guidance, EP forecast reset, margins, and strategic review highlights—read the key takeaways.

There is no deadline for the review and no assurance it will result in a transaction. Integer separately lowered its outlook for 2026, citing headwinds with three of its products.

Integer Holdings cut its 2026 sales and earnings forecasts due to reduced customer orders in its electrophysiology segment and broader risk adjustments, while stressing the changes are temporary.